BioMarin and Ascendis stock prices decline due to BridgeBio's strong achondroplasia data

LootboxPhobia · 2026-02-12T13:24:52+00:00

After competitor BridgeBio Pharma announced positive clinical data for the cartilage dysplasia treatment drug infigratinib, the stock prices of BioMarin and Ascendis Pharma dropped about 6%. The drug showed significant efficacy in trials and could pose a threat to BioMarin's Voxzogo.

LootboxPhobia

2026-02-12 13:24:52

Abstract generation in progress

Investing.com – Following the positive clinical trial results of its cartilage dysplasia treatment drug by competitor BridgeBio Pharma (NASDAQ:BBIO), the stock prices of BioMarin Pharmaceutical (NASDAQ:BMRN) and Ascendis Pharma (NASDAQ:ASND) both declined by approximately 6%.

BridgeBio announced that its oral drug infigratinib achieved the primary endpoint in the Phase 3 PROPEL 3 study, demonstrating a superior annual height velocity compared to placebo, with an average treatment difference of +2.10 centimeters per year. The drug also achieved statistically significant improvements in body proportion compared to placebo in a randomized cartilage dysplasia trial for the first time.

This positive data poses a potential competitive threat to BioMarin’s Voxzogo, which is currently the only FDA-approved treatment for cartilage dysplasia.

Ascendis Pharma’s stock also declined following this news. The company’s weekly injection therapy for cartilage dysplasia is currently under FDA review and may be approved before February 28.

BridgeBio’s oral infigratinib may have a significant advantage over injectable competitors, as it demonstrated strong efficacy without serious adverse events related to the study drug. The company plans to submit regulatory applications in the second half of 2026.

Cartilage dysplasia is a hereditary disorder affecting bone growth, occurring in approximately 1 in 15,000 to 40,000 newborns, estimated to impact about 55,000 people in the US and EU.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.